Dublin, 28 August 2020 (GLOBE NEWSWIRE) – Added “Molecular Diagnostic Markets in the COVID-19 Era (Molecular COVID-19 IVD Testing Markets, Respiratory Tests, Blood Tests, Cancer Markers and Other IVD Testing)” Offer of ResearchAndMarkets.com.
Today more than ever, molecular diagnosis is the ultimate component of in vitro diagnosis. The analyst, for many years, has estimated the expected duration and expansion of the global molecular diagnostics market across all primary segments, and is doing so in this edition as a pandemic has reached evolved markets, adding to the United States.
This will not be the case universally. In areas of testing other than COVID-19, such as cancer and inherited diseases, molecular diagnostic providers will need to continue to convince. Here volumes can be reduced by social distance measures. But they continue to make progress in converting lab customers. New technologies such as next-generation, patient-friendly molecular sequencing are increasingly a component of the mix. The report mainly points to these trends.
There has also been a huge influx of product introductions from small, obscure companies. These have mostly targeted the low end of the price range and often had poor performance, while a small number of high-end automated systems are mostly limited to certain segments of the market, such as independent reference laboratories and centralized hospital laboratories. Low-quality products from fly-by-night companies are the predictable result of the shortages and the relatively basic resources needed to produce mediocre antibody test kits with a low level of quality control. A few major companies are seeing the most test runs, particularly in the United States.COVID-19 testing has also been a bit of a double-edged sword for labs generally, for in vitro diagnostics and for molecular tests. Boosting volumes in infectious disease have been notably paired with drops due to social distancing measures and hospital surgical postponements. What is the result? The report helps to sort out the array of news and reports about the current state of molecular diagnostics, reasonable global estimates for COVID, and the impact of COVID-19 on the rest of molecular testing.The report covers the global markets. For All Markets, the analyst provides the following:
The analyst monitored 2020 secondary sources, advertising publications, medical journals, government internet sites and policy documents, as well as providers’ monetary statements to assess that the market has an effect on COVID-19. In addition, the analyst has been tracking lab volumes with research since mid-April, and the American product of analyst MasterFile has been used to track tool trends.
Chapter One: Analytical Summary
Chapter Two: COVID-19
Chapter Five: Molecular Blood Testing Markets
Chapter Six: Diagnostic Markets in Molecular Histology and Cytology
Chapter Seven: Markets for Molecular Diagnosis of Cancer
Chapter Nine: Markets for the Diagnosis of Molecular Hereditary Diseases
Chapter Ten: Business Profiles
For more information on this report, https://www.researchandmarkets.com/r/9eza8i
Reseek and Markets also offers custom searches that offer a targeted, complete and personalized search.